Management of acute dyspnoea: Use and feasibility of brain natriuretic peptide (BNP) assay in the prehospital setting

Resuscitation

Volumn 61, Issue 1, 2004, Pages 91-96

  Teboul, Alexandre ^a   Gaffinel, Alain ^a   Meune, Christophe ^b   Greffet, Agnès ^a   Sauval, Patrick ^a   Carli, Pierre ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

^b NONE   (France)

Author keywords

Ambul ncia; Ambulance; Ambulancia; Brain natriuretic peptide; Dispneia; Dyspnoea; Emergency medical services; Fal ncia card aca; Heart failure; Pet deo natriur tico cerebral; Servi os m dicos de emerg ncia

Indexed keywords

BRAIN NATRIURETIC PEPTIDE;

ACUTE DISEASE; ADULT; AGED; ARTICLE; BRONCHOSPASM; CLINICAL FEATURE; CONTROLLED STUDY; DYSPNEA; EVALUATION; FEASIBILITY STUDY; FEMALE; HEALTH SERVICE; HEART DISEASE; HEART LEFT VENTRICLE FAILURE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEASUREMENT; PATIENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN DETERMINATION; RESPIRATORY TRACT DISEASE;

ACUTE DISEASE; AGED; AGED, 80 AND OVER; DIAGNOSIS, DIFFERENTIAL; DYSPNEA; EMERGENCY MEDICAL SERVICES; FEASIBILITY STUDIES; FEMALE; HEART DISEASES; HUMANS; MALE; MIDDLE AGED; NATRIURETIC PEPTIDE, BRAIN; PROSPECTIVE STUDIES; RESPIRATION DISORDERS;

EID: 1842687901     PISSN: 03009572     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.resuscitation.2003.12.005     Document Type: Article

References (33)

1. Télion C., Greffet A., Rozenberg A.et al. L'admission directe en service de réanimation ou de soins intensifs des patients pris en charge par le SMUR est-elle justifiée? Ann. Fr. Anesth. Réanim. 19:2000;654-661.
2. Sudoh T., Minamino N., Kangawa K. A new natriuretic peptide in human brain. Nature. 332:1988;78-81.
3. Ogawa Y., Nakao K., Mukoyama M. Rat brain natriuretic peptide tissue distribution and molecular form. Endocrinology. 126:1990;2225-2227.
4. Hosoda K., Nakao K., Mukoyama M. Expression of brain natriuretic peptide gene in human heart. Hypertension. 17:1991;1152-1156.
5. Yasue H., Yoshimura M., Sumida H. Localisation and mechanism of secretion of B type natriuretic peptide in comparison with those of A type natriuretic peptide in normal subjects and patients with heart failure. Circulation. 90:1994;195-203.
6. Nagagawa O., Ogawa Y., Itoh H.et al. Rapid transcriptional activation and early mRNA turnover of BNP in cardiocyte hypertrophy: evidence for BNP as an "emergency" cardiac hormone against ventricular overload. J. Clin. Invest. 96:1995;1280-1287.
7. Dickstein K. Natriuretic peptides in detection of heart failure. Lancet. 35:1998;3-4.
8. Mukoyama M., Nakao K., Hosoda K. Brain natriuretic peptide as a novel hormone in humans: evidence for an exquisite dual natriuretic peptide system. J. Clin. Invest. 87:1991;1402-1412.
9. Cabanes L., Richaud-Thiriez B., Fulla Y.et al. Brain natriuretic peptide blood levels in the differential diagnosis of dyspnea. Chest. 120:2001;2047-2050.
10. Omland T., Aakvaag A., Vik-Mo H. Plasma cardiac natriuretic peptide determination as a screening test for detection of patients with mild left ventricular impairment. Heart. 76:1996;232-237.
11. Yamamoto K., Burnett J.C. Jr., Jougasaki M.et al. Hypertension. 28:1996;988-994.
12. Davidson N.C., Naas A.A., Hanson J.K.et al. Comparison of atrial natriuretic peptide, B-type natriuretic peptide, and N-terminal proatrial natriuretic peptide as indicators of left ventricular systolic dysfunction. Am. J. Cardiol. 77:1996;828-831.
13. Sagnella G.A. Measurement and significance of circulating natriuretic peptides in cardiovascular disease. Clin. Sci. 95:1998;519-529.
14. Friedl W., Mair J., Thomas S.et al. Natriuretic peptides and cyclic guanosine 3′.5′-monophosphate in asymptomatic and symptomatic left ventricular dysfunction. Heart. 76:1996;129-136.
15. Muders F., Kromer E.P., Griese D.P.et al. Evaluation of plasma natriuretic peptides as markers for left ventricular dysfunction. Am. Heart. J. 134:1997;442-449.
16. Yamada Y., Goto J., Yokoto M. Brain natriuretic peptide is a sensitive indicator of impaired left ventricular dysfunction in elderly patients with cardiovascular disease. Cardiology. 88:1997;401-407.
17. Mc Donagh T.A., Robb S.D., Murdoch D.R.et al. Biochemical detection of left ventricular dysfunction. Lancet. 351:1998;9-13.
18. Selvais P.L., Donckier J.E., Robert A.et al. Cardiac natriuretic peptides for diagnosis and risk stratification in heart failure : influences of left ventricular dysfunction and coronary artery on cardiac hormonal activation. Eur. J. Clin. Invest. 28:1998;636-642.
19. Richards A.M., Nicholls M.G., Yandle T.G.et al. Neuroendocrine prediction of left ventricular function and heart failure after acute myocardial infarction. Heart. 81:1999;114-120.
20. Struthers A.D. Plasma concentration of brain natriuretic peptide: will this new test reduce the need for cardiac investigations? Br. Heart J. 70:1993;397-398.
21. Harrison A., Morrison L., Krishnaswamy P.et al. B-natriuretic peptide predicts future cardiac events in patients presenting to the emergency department with dyspnoea. Ann. Emerg. Med. 39:2002;131-138.
22. Wei C., Heublein D., Perella M. Natriuretic peptide system in human heart failure. Circulation. 88:1993;1004-1009.
23. Tsutamoto T., Wada A., Maeda K.et al. Attenuation of compensation of endogenous cardiac natriuretic peptide system in chronic heart failure: prognostic role of a plasma brain natriuretic peptide concentration in patients with chronic symptomatic left ventricular dysfunction. Circulation. 96:1997;509-516.
24. Lambert Y, Milojevic K, Nédellec P., et al. Les examens de laboratoire en préhospitalier. In: SFAR, editor. Médecine d'Urgence: Paris: Elsevier; 1998. p. 11-9.
25. Kost GJ. Point-of-care testing in intensive care. In: Tobin MJ, editor. Principles and practice in intensive care monitoring. New York: McGraw-Hill; 1997. p. 1267-96
26. Misiano D.R., Meyerhoff M.E., Collison M.E. Current and future directions in the technology relating to bedside testing in critically ill patients. Chest. 97:1990;240-241.
27. Dao Q., Krishnaswamy P., Kazanegra R.et al. Utility of B-type natriuretic peptide in the diagnosis of congestive heart failure in an urgent-care setting. J. Am. Coll. Cardiol. 37:2001;379-385.
28. Maisel A., Krishnaswamy P., Nowak R.et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. NEJM. 347:2002;161-167.
29. Voseger M., Jacob K. B-type natriuretic peptide (BNP)-validation of an immediate response assay. Clin. Lab. 47:2001;29-33.
30. Gérard JL, Hanouz JL. Traitement de l'insuffisance cardiaque aiguë. In: SFAR, editor. Conférences d"actualisation. Paris: Elsevier; 1999. p. 519-37
31. Davis M., Espiner E., Richards G.et al. Plasma brain natriuretic peptide in assessment of acute dyspnoea. Lancet. 343:1994;440-444.
32. Morrison L., Harrison A., Krishnaswamy P.et al. Utility of a rapid B-natriuretic peptide assay in differentiating congestive heart failure from lung disease in patients presenting with dyspnoea. JAAC. 39:2002;202-209.
33. Wuerz R., Meador S. Effects of prehospital medications on mortality and length of stay in congestive heart failure. Ann. Emerg. Med. 21:1992;669-674.